Float Short %

10.14

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.05

EPS Last/This Y

-0.44

EPS This/Next Y

0.18

Price

15.48

Target Price

31.6

Analyst Recom

1.06

Performance Q

13.4

Relative Volume

1.69

Beta

1.22

Ticker: DNLI

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	DNLI	13.63	0.17	0.50	1210
2025-07-29	DNLI	13.61	0.17	0.00	1219
2025-07-30	DNLI	13.67	0.17	0.43	1228
2025-07-31	DNLI	13.83	0.17	1.60	1230
2025-08-01	DNLI	13.43	0.17	0.50	1241
2025-08-04	DNLI	14.43	0.17	0.10	1244
2025-08-05	DNLI	14.28	0.17	0.00	1250
2025-08-06	DNLI	14.35	0.17	0.00	1263
2025-08-07	DNLI	14.25	0.17	1.00	1264
2025-08-08	DNLI	13.98	0.17	0.19	1268
2025-08-11	DNLI	13.91	0.17	0.14	1287
2025-08-12	DNLI	13.24	0.18	1.00	1320
2025-08-13	DNLI	14.83	0.18	0.77	1324
2025-08-14	DNLI	14.45	0.19	999.99	1342
2025-08-15	DNLI	14.71	0.19	0.00	1346
2025-08-18	DNLI	14.81	0.10	0.99	916
2025-08-19	DNLI	14.81	0.34	0.00	1522
2025-08-20	DNLI	14.51	0.34	0.00	1535
2025-08-21	DNLI	15.23	0.30	0.45	1662
2025-08-22	DNLI	15.48	0.30	0.20	1677
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	DNLI	13.66	-24.6	166.7	-3.06
2025-07-29	DNLI	13.61	-24.6	167.1	-3.06
2025-07-30	DNLI	13.67	-24.6	164.3	-3.06
2025-07-31	DNLI	13.83	-24.6	159.8	-3.06
2025-08-01	DNLI	13.44	-24.6	182.2	-3.06
2025-08-04	DNLI	14.44	-24.6	122.6	-3.06
2025-08-05	DNLI	14.29	-24.6	172.3	-3.06
2025-08-06	DNLI	14.36	-24.6	163.7	-3.06
2025-08-07	DNLI	14.23	-24.6	171.0	-3.06
2025-08-08	DNLI	13.96	-24.6	176.8	-3.06
2025-08-11	DNLI	13.91	-24.6	168.0	-3.06
2025-08-12	DNLI	13.22	-24.6	194.6	-3.06
2025-08-13	DNLI	14.81	-16.8	109.2	-3.06
2025-08-14	DNLI	14.44	-16.8	199.0	-3.06
2025-08-15	DNLI	14.71	-24.6	174.5	-3.00
2025-08-18	DNLI	14.81	-24.6	180.3	-3.00
2025-08-19	DNLI	14.81	-20.1	79.7	-3.00
2025-08-20	DNLI	14.51	-20.1	93.8	-3.00
2025-08-21	DNLI	15.23	-20.1	40.9	-3.00
2025-08-22	DNLI	15.48	-20.1	66.8	-3.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	DNLI	-2.47	4.55	10.09
2025-07-29	DNLI	-2.47	4.55	10.09
2025-07-30	DNLI	-2.47	4.55	10.09
2025-07-31	DNLI	-2.47	4.55	10.09
2025-08-01	DNLI	-2.47	4.55	10.09
2025-08-04	DNLI	-2.47	3.68	10.09
2025-08-05	DNLI	-2.47	3.68	10.09
2025-08-06	DNLI	-2.47	3.68	10.09
2025-08-07	DNLI	-2.47	3.68	10.09
2025-08-08	DNLI	-2.47	3.68	10.09
2025-08-11	DNLI	-2.47	3.75	10.09
2025-08-12	DNLI	-2.46	3.75	10.21
2025-08-13	DNLI	-2.46	3.75	10.21
2025-08-14	DNLI	-2.45	3.75	10.14
2025-08-15	DNLI	-2.48	3.75	10.14
2025-08-18	DNLI	-2.48	3.66	10.14
2025-08-19	DNLI	-2.48	3.66	10.14
2025-08-20	DNLI	-2.48	3.66	10.14
2025-08-21	DNLI	-2.48	3.66	10.14
2025-08-22	DNLI	-2.48	3.66	10.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.72

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-2.48

Institutional Transactions

3.66

Beta

1.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

83.5

Max Drawdown 5-Year %

-87.7

Target Price

31.6

P/E

Forward P/E

PEG

P/S

P/B

2.2

P/Free Cash Flow

EPS

-2.81

Average EPS Est. Cur. Y

-3.01

EPS Next Y. (Est.)

-2.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.69

Return on Equity vs Sector %

-71.3

Return on Equity vs Industry %

-58.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.05

EBIT Estimation

66.8

Denali Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 486

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today

news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance

stock history DNLI – Denali Therapeutics Inc. invest stock market

stock prices DNLI premarket after hours

ticker DNLI fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: DNLI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y